Complete biochemical response after stereotactic ablative radiotherapy of an isolated prostate cancer pelvic soft tissue recurrence detected by 18F-DCFPyL PET/CT

Complete biochemical response after stereotactic ablative radiotherapy of an isolated prostate cancer pelvic soft tissue recurrence detected by 18F-DCFPyL PET/CT

Bibliographic Details
Main Authors:	Ryan M. Phillips, Michael A. Gorin, Steven P. Rowe, Martin G. Pomper, Kenneth J. Pienta, Ashley E. Ross, Phuoc T. Tran
Format:	Article
Language:	English
Published:	Elsevier 2018-01-01
Series:	Urology Case Reports
Subjects:	Prostate cancer Local recurrence PSMA Molecular imaging Radiotherapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2214442017302905

Similar Items

18F-DCFPyL PET/CT in primary staging of prostate cancer
by: Maurits Wondergem, et al.
Published: (2018-10-01)

Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [18F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation
by: Eugene Shenderov, et al.
Published: (2018-03-01)

Evaluation of 18F-DCFPyL PSMA PET/CT for Prostate Cancer: A Meta-Analysis
by: Ke-Hao Pan, et al.
Published: (2021-02-01)

Competitive blocking of salivary gland [18F]DCFPyL uptake via localized, retrograde ductal injection of non-radioactive DCFPyL: a preclinical study
by: Jyoti Roy, et al.
Published: (2021-07-01)

Intra-patient comparison of physiologic 68Ga-PSMA-11 and 18F-DCFPyL PET/CT uptake in ganglia in prostate cancer patients: a pictorial essay
by: Medhat M. Osman, et al.
Published: (2021-04-01)

Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution
by: Gonçalo Ferreira, et al.
Published: (2019-05-01)

Uptake of prostate-specific membrane antigen-targeted18F-DCFPyL in avascular necrosis of the femoral head
by: Gonzalo Torga, et al.
Published: (2019-01-01)

PSMA-targeted [18F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework
by: Diane K. Reyes, et al.
Published: (2019-03-01)

Kinetic analysis of dominant intraprostatic lesion of prostate cancer using quantitative dynamic [18F]DCFPyL-PET: comparison to [18F]fluorocholine-PET
by: Dae-Myoung Yang, et al.
Published: (2021-01-01)

PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer
by: Charlotte L. Deijen, et al.
Published: (2021-09-01)

Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging
by: Wei Liu, MD, et al.
Published: (2021-01-01)

Vas deferens infiltration by prostate cancer on prostate-specific membrane antigen-targeted18F-DCFPyL positron emission tomography/computed tomography: A unique visual pattern
by: Yafu Yin, et al.
Published: (2019-01-01)

A Pilot Study of 18F-DCFPyL PET/CT or PET/MRI and Ultrasound Fusion Targeted Prostate Biopsy for Intra-Prostatic PET-Positive Lesions
by: Yachao Liu, et al.
Published: (2021-03-01)

Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer.
by: Dennie Meijer, et al.
Published: (2020-01-01)

Direct comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer.
by: Batool Albalooshi, et al.
Published: (2020-01-01)

<sup>68</sup>Ga-PSMA-11 PET/CT-Guided Stereotactic Body Radiation Therapy Retreatment in Prostate Cancer Patients with PSA Failure after Salvage Radiotherapy
by: Paola Caroli, et al.
Published: (2020-11-01)

Uptake in non-affected bone tissue does not differ between [18F]-DCFPyL and [68Ga]-HBED-CC PSMA PET/CT.
by: Jochen Hammes, et al.
Published: (2018-01-01)

Standardized uptake values are adequate measures of [18F]DCFPyL PSMA PET/CT uptake in patients with low prostate cancer disease burden
by: Y.J.L. Bodar, et al.
Published: (2020-11-01)

Performance of 18F-DCFPyL PET/CT Imaging in Early Detection of Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-Analysis
by: Jiale Sun, et al.
Published: (2021-04-01)

Diagnostic Role of <sup>18</sup>F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review
by: Salam Awenat, et al.
Published: (2021-03-01)

68Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer
by: Amir Iravani, et al.
Published: (2017-12-01)

Detection Rate of <sup>18</sup>F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis
by: Giorgio Treglia, et al.
Published: (2019-05-01)

PET/CT-Based Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy: Impact on Treatment Management and Future Directions
by: Jennifer le Guevelou, et al.
Published: (2021-08-01)

Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT)
by: Gregor Habl, et al.
Published: (2017-05-01)

68Ga–Prostate-Specific Membrane Antigen: A Potential Radiopharmaceutical in PET/CT To detect primary Cholangiocarcinoma
by: Rita Chahinian, et al.
Published: (2020-07-01)

Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers—Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT
by: Rudolf A. Werner, et al.
Published: (2019-07-01)

Interobserver agreement of [68Ga]Ga-PSMA-11 PET/CT images interpretation in men with newly diagnosed prostate cancer
by: Céline Derwael, et al.
Published: (2020-02-01)

Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy
by: Nina-Sophie Schmidt-Hegemann, et al.
Published: (2018-03-01)

A Multi-Institutional Analysis of Prostate Cancer Patients With or Without 68Ga-PSMA PET/CT Prior to Salvage Radiotherapy of the Prostatic Fossa
by: Nina-Sophie Schmidt-Hegemann, et al.
Published: (2021-10-01)

Evaluation of SUV normalized by lean body mass (SUL) in 68Ga-PSMA11 PET/CT: a bi-centric analysis
by: Andrei Gafita, et al.
Published: (2019-12-01)

A survey among German-speaking radiation oncologists on PET-based radiotherapy of prostate cancer
by: Marco M. E. Vogel, et al.
Published: (2021-05-01)

Mesorectal Lymph Node Metastases as Index Lesion in 68Ga-PSMA-PET/CT Imaging for Recurrent Prostate Cancer
by: Conrad Leitsmann, et al.
Published: (2021-03-01)

Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy
by: Ann-Kathrin Oehus, et al.
Published: (2020-04-01)

Synthesis and preclinical evaluation of novel 18F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with 18F-DCFPyl and 18F-PSMA-1007
by: Stephanie Robu, et al.
Published: (2018-04-01)

Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer
by: Christoph Henkenberens, et al.
Published: (2021-04-01)

Optimization of [18F]PSMA-1007 PET-CT using regularized reconstruction in patients with prostate cancer
by: Elin Trägårdh, et al.
Published: (2020-05-01)

Targeted Prostate Biopsy Using 68Gallium PSMA-PET/CT for Image Guidance
by: Demetrios N. Simopoulos, et al.
Published: (2017-09-01)

68Ga-PSMA-PET/CT for the evaluation of liver metastases in patients with prostate cancer
by: Jonathan Damjanovic, et al.
Published: (2019-06-01)

Optimized Application of 68Ga-Prostate-Specific Membrane Antigen-617 Whole-Body PET/CT and Pelvic PET/MR in Prostate Cancer Initial Diagnosis and Staging
by: Chunxia Qin, et al.
Published: (2021-05-01)

Comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer: a protocol for systematic review and meta-analysis
by: Garba Haruna Yunusa, et al.
Published: (2021-07-01)